A Role for Angiotensin II Type 1 Receptors on Bone Marrow-Derived Cells in the Pathogenesis of Angiotensin II–Dependent Hypertension
- 1 January 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 55 (1) , 99-108
Abstract
Activation of type 1 angiotensin (AT1) receptors causes hypertension, leading to progressive kidney injury. AT1receptors are expressed on immune cells, and previous studies have identified a role for immune cells in angiotensin II–dependent hypertension. We, therefore, examined the role of AT1receptors on immune cells in the pathogenesis of hypertension by generating bone marrow chimeras with wild-type donors or donors lacking AT1Areceptors (BMKO). The 2 groups had virtually identical blood pressures at baseline, suggesting that AT1receptors on immune cells do not make a unique contribution to the determination of baseline blood pressure. By contrast, in response to chronic angiotensin II infusion, the BMKOs had an augmented hypertensive response, suggesting a protective effect of AT1receptors on immune cells with respect to blood pressure elevation. The BMKOs had 50% more albuminuria after 4 weeks of angiotensin II–dependent hypertension. Angiotensin II–induced pathological injury to the kidney was similar in the experimental groups. However, there was exaggerated renal expression of the macrophage chemokine monocyte chemoattractant protein 1 in the BMKO group, leading to persistent accumulation of macrophages in the kidney. This enhanced mononuclear cell infiltration into the BMKO kidneys was associated with exaggerated renal expression of the vasoactive mediators interleukin-1β and interleukin-6. Thus, in angiotensin II–induced hypertension, bone marrow–derived AT1receptors limited mononuclear cell accumulation in the kidney and mitigated the chronic hypertensive response, possibly through the regulation of vasoactive cytokines.Keywords
This publication has 58 references indexed in Scilit:
- Regulation of T-cell function by endogenously produced angiotensin IIAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- Interleukin-1β, but not interleukin-6, enhances renal and systemic endothelin production in vivoAmerican Journal of Physiology-Renal Physiology, 2008
- Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertensionAmerican Journal of Physiology-Renal Physiology, 2008
- Involvement of Tumor Necrosis Factor-α in Angiotensin II–Mediated Effects on Salt Appetite, Hypertension, and Cardiac HypertrophyHypertension, 2008
- Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in miceJournal of Clinical Investigation, 2008
- Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunctionJournal of Experimental Medicine, 2007
- Interleukin 1-beta (IL-1β) enhances contractile responses in endothelium-denuded aorta from hypertensive, but not normotensive, ratsVascular Pharmacology, 2007
- Angiotensin II type 1 receptor blockade attenuates TGF-β–induced failure of muscle regeneration in multiple myopathic statesNature Medicine, 2007
- Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusionsAmerican Journal of Physiology-Renal Physiology, 2007
- Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidneyProceedings of the National Academy of Sciences, 2006